Clinicopathologic Features of BRAF V600E-Mutant Anaplastic Thyroid Carcinoma

被引：0
|
作者：
Chen, Tiffany
Wong, Kristine [1 ]
Barletta, Justine [2 ]
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
574
引用
收藏
页码：571 / 572
页数：2
相关论文
共 50 条
  • [31] BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma
    Lim, Annette M.
    Taylor, Graham R.
    Fellowes, Andrew
    Cameron, Laird
    Lee, Belinda
    Hicks, Rodney J.
    McArthur, Grant A.
    Angel, Christopher
    Solomon, Benjamin
    Rischin, Danny
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (03): : 249 - 254
  • [32] Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter
    Huillard, Olivier
    Tenenbaum, Florence
    Clerc, Jerome
    Goldwasser, Francois
    Groussin, Lionel
    CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5639 - 5639
  • [33] Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma
    Jung, Yoon Yang
    Yoo, Jae Hyung
    Park, Eon Sub
    Kim, Mi Kyung
    Lee, Tae Jin
    Cho, Bo Youn
    Chung, Yun Jae
    Kang, Kyung Ho
    Ahn, Hwa Young
    Kim, Hee Sung
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (02) : 162 - 170
  • [34] Relationship between BRAF V600E and clinica features in papillary thyroid carcinoma
    Yan, Changjiao
    Huang, Meiling
    Li, Xin
    Wang, Ting
    Ling, Rui
    ENDOCRINE CONNECTIONS, 2019, 8 (07): : 988 - 996
  • [35] The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma
    Lin, Zi-Mei
    Yan, Cao-Xin
    Song, Yue
    Hong, Yu-Rong
    Wen, Qing
    Xu, Yong-Yuan
    Pan, Min-Qiang
    Ye, Qin
    Huang, Pin-Tong
    JOURNAL OF THORACIC DISEASE, 2019, 11 (12) : 5071 - 5078
  • [36] Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
    Robinson, Giles W.
    Orr, Brent A.
    Gajjar, Amar
    BMC CANCER, 2014, 14
  • [37] Identification of BRAF p. V600E-Mutant and Wild-Type by MR Imaging in Pleomorphic Xanthoastrocytoma and Anaplastic Pleomorphic Xanthoastrocytoma
    Huang, W.
    Cai, J.
    Lin, N.
    Xu, Y.
    Wang, H.
    Wu, Z.
    Kang, D.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2021, 42 (12) : 2152 - 2159
  • [38] Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
    Xu, Ting
    Wang, Xicheng
    Wang, Zhenghang
    Deng, Ting
    Qi, Changsong
    Liu, Dan
    Li, Yanyan
    Ji, Congcong
    Li, Jian
    Shen, Lin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [39] Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
    Li, Qian
    Yuan, Jianjun
    Wang, Yan
    Zhai, Yuanpeng
    ONCOLOGY LETTERS, 2017, 14 (02) : 1439 - 1444
  • [40] BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series
    Sabeeh-ur-Rehman Butt
    Alberto Mejias
    Cristina Morelli
    Gonzalo Torga
    Marlene Happe
    Anna Patrikidou
    Hendrik-Tobias Arkenau
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 437 - 441
12345